Millennium Pharmaceuticals Limited

Aileron Therapeutics, Inc.

Nimbus Iris, Inc.

Bayer Corporation

Millenium Pharmaceuticals, Inc.

Bayer Healthcare Aktiengesellschaft

Rome Therapeutics, Inc.

Rosana Kapeller-Libermann

Mark Williamson

Rachel E Meyers

Rory A J Curtis

Nadine Weich

Kyle J MacBeth

Peter J Olandt

Tomi K Sawyer

Huw M Nash

Noriyuki Kawahata

David W White

William James Cook

John Joseph Hunter

Rajasekhar Bandaru

Miyoung Chun

Craig E Masse

Jeremy Robert Greenwood

Donna Lee Romero

Geraldine C Harriman

Ronald Thure Wester

Mee Shelley

Shaughnessy Robinson

Laura A Rudolph-Owen

David Allen Annis

Ruth E Gimeno

Fong-Ying Tsai

Joseph M Carroll

Zhidan Wu

Thomas Joseph Logan

Brian K Hubbard

Inmaculada Silos-Santiago

Frank Spaltmann

Helga Rubsamen-Waigmann

Susan Laurene Acton

Maria Alexandra Glucksmann

Mehran M Khodadoust

Matthew David Wessel

Rachel A Meyers

Kevin R Leiby

Jiawen Han

Katherine M Galvin

Immaculada Silos-Santiago

Jia-Wen Han

Karen L Anderson

Rajesekhar Bandaru

Keith E Robision

Justin Noehre

Donna L Romero

Oliver Saunders

Gregory Stuart Bisacchi

Dennis Zaller

The invention provides compounds, compositions and methods for treating medical disorders, such as cancer, an autoimmune disorder, and/or a neurological disorder, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase using a compound according to Formula I or a pharmaceutically acceptable salt thereof, or a related compound provided herein.

Compounds and methods for treating disease

Disclosed are peptidomimetic macrocycles comprising a helix, such as an alpha helix, and methods of using such macrocycles for the treatment of disease such as cancer. In other aspects, the peptidomimetic macrocycle comprises an &#x3b1;,&#x3b1;-disubstituted amino acid, or may comprise a crosslinker linking the &#x3b1;-positions of at least two amino acids or at least one of said two amino acids may be an &#x3b1;,&#x3b1;-disubstituted amino acid. Further included is the targeting of components of the Wnt signaling pathway such as the Tcf4-/3-catenin complex.

Peptidomimetic macrocycles

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK inhibitors and uses thereof

The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.

Peptidomimetic macrocycles with improved properties

The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease.

Therapeutic peptidomimetic macrocycles

Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides; and methods of making and identifying such improved polypeptides.

The present invention relates to compositions and methods for the diagnosis and treatment of obesity and related metabolic disorders. The invention provides isolated nucleic acids molecules, designated DGAT2 family member nucleic acid molecules, which encode diacylglycerol acyltransferase family members. The invention also provides recombinant expression vectors containing DGAT2 family member nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DGAT2 family member gene has been introduced or disrupted. The invention still further provides isolated DGAT2 family member proteins, fusion proteins, antigenic peptides and anti-DGAT2 family member antibodies. Methods of use of the provided DGAT2 family member compositions for screening, diagnostic and therapeutic methods in connection with obesity disorders are also disclosed.

Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor

The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.

17867, a novel human aminopeptidase

The invention provides isolated nucleic acid molecules, designated ACTR-1 nucleic acid molecules, which encode novel acyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ACTR-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ACTR-1 gene has been introduced or disrupted. The invention still further provides isolated ACTR-1 proteins, fusion proteins, antigenic peptides and anti-ACTR-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

ACTR-1, a novel human acyltransferase and uses thereof

The invention relates to novel kinase nucleic acid sequences and proteins. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.

Human protein kinases and uses therefor

The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted. The invention still further provides isolated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 proteins, fusion proteins, antigenic peptides and anti-21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor

Growing community of inventors

Chestnut Hill, MA, United States of America

Rosana Kapeller-Libermann